샘플 요청 목록

 카트 문의
시장보고서
상품코드
1595054

세계의 조직공학 피부 대체물 시장

Tissue Engineered Skin Substitutes
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 89 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 조직공학 피부 대체물 시장은 2030년까지 54억 달러에 도달

2023년에 31억 달러로 추정되는 세계의 조직공학 피부 대체물 시장은 분석 기간인 2023-2030년에 CAGR 8.2%로 성장하며, 2030년에는 54억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 생물학적 대체물은 CAGR 8.8%를 기록하며, 분석 기간 종료시에는 29억 달러에 달할 것으로 예상됩니다. 합성 대체품 부문의 성장률은 분석 기간 중 CAGR 8.0%로 추정됩니다.

미국 시장은 8억 5,300만 달러로 추정, 중국은 CAGR 7.6%로 성장 예측

미국의 조직공학 피부 대체물 시장은 2023년에 8억 5,300만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2023-2030년 CAGR 7.6%로 추이하며, 2030년에는 8억 2,250만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 7.6%와 6.6%로 예측됩니다. 유럽에서는 독일이 CAGR 약 6.5%로 성장할 것으로 예측됩니다.

세계의 조직공학 피부 대체물 시장 - 주요 동향과 촉진요인 정리

조직공학 피부 대체물은 창상관리에 어떤 혁명을 일으키고 있는가?

조직공학 피부 대체물은 중증 화상, 만성 창상, 기타 피부 손상을 입은 환자의 손상되거나 손실된 피부 조직을 대체하기 위해 고안된 첨단 생체 재료입니다. 이러한 대체물은 생체 적합성 스캐폴드, 세포 및 성장 인자를 사용하여 개발되어 자연 피부의 구조와 기능을 모방하여 더 빠른 치유를 촉진하고 흉터를 감소시킵니다. 동종 이식, 자가 이식, 이종 이식으로 제공되는 조직공학 피부 대체물은 재건 수술, 피부과 및 상처 관리에 필수적인 솔루션을 제공합니다. 의료 시스템이 환자의 예후 개선과 조기 회복을 중시하는 가운데, 조직공학 피부 대체물은 기존 피부 이식을 대체할 수 있는 효과적인 대안으로 각광받고 있습니다.

조직공학 피부 대체물 시장의 주요 부문은?

주요 제품 유형에는 세포 대체물, 세포 대체물, 복합 대체물이 있습니다. 주로 콜라겐 및 기타 생체 재료로 만든 세포 대체물은 화상 치료 및 만성 상처 관리에 널리 사용되므로 큰 점유율을 차지하고 있습니다. 살아있는 세포를 포함하는 세포 대체물은 환자의 피부와 통합되어 치유를 촉진하는 능력으로 인해 인기를 얻고 있습니다. 조직공학 피부 대체물의 용도에는 화상 관리, 당뇨성 궤양, 욕창, 재건 수술 등이 포함되며, 화상 관리는 중증 환자에서 빠른 피부 재생이 매우 중요하므로 가장 큰 비중을 차지합니다. 조직공학 피부 대체물의 최종사용자에는 병원, 상처 치료 센터, 전문 클리닉 등이 포함됩니다. 병원은 시장을 선도하고 있으며, 화상 치료, 재건 수술, 만성 상처 관리 등 빠른 치유와 입원 기간 단축이 중요한 경우에 이러한 대체재를 사용하고 있습니다. 상처 치료 센터는 당뇨병성 궤양, 욕창 및 기타 치유되지 않는 상처를 치료하기 위해 피부 대체물을 사용하여 환자의 회복을 개선하고 감염 위험을 줄입니다. 또한 전문 클리닉에서는 미용 성형 및 재건 수술에 이러한 대용품을 사용하여 더 나은 미적 결과와 더 빠른 회복 시간을 달성합니다.

조직공학 피부 대체물은 어떻게 헬스케어에 적용되고 있는가?

병원에서 조직공학 피부 대체물은 심한 화상, 깊은 상처, 수술 후 회복에 사용되어 빠른 치유를 촉진하고 흉터 형성을 최소화하는 데 도움이 됩니다. 상처 치료 센터에서는 당뇨병성 궤양이나 욕창과 같은 만성 상처 관리에 중요한 역할을 하며, 피부 조직 재생과 감염을 예방하는 데 도움이 됩니다. 재건 및 미용 수술에서 피부 대체물은 특히 외상, 선천적 결손, 암 수술 후 등의 경우에 심미적 회복과 피부 기능 개선에 도움을 줍니다. 또한 이러한 피부 대체물에 첨단 생체 재료를 사용하면 기증자 피부 이식의 필요성을 줄이고 합병증과 회복 시간을 최소화할 수 있습니다.

조직공학 피부 대체물 시장의 성장을 가속하는 요인은 무엇인가?

조직공학 피부 대체물 시장의 성장은 화상 및 만성 상처의 발병률 증가, 조직공학의 발전, 더 나은 상처 치료 솔루션에 대한 수요 증가 등 여러 가지 요인에 의해 주도되고 있습니다. 생체공학적 스캐폴딩, 성장인자 주입 대체재, 천연 조직과의 통합성 향상 등의 혁신으로 인해 헬스케어 전반에 걸쳐 적용이 확대되고 있습니다. 환자 예후 개선, 회복 시간 단축, 입원 기간 최소화에 중점을 둔 조직공학 피부 대체물은 상처 관리에 중요한 이점을 제공함으로써 수요를 더욱 촉진하고 있습니다. 또한 의료비 지출 증가, 첨단 상처 치료에 대한 인식 증가, 재생의료에 대한 투자 증가가 시장 성장에 기여하고 있으며, 다양한 의료 현장에서 조직공학 피부 대체물의 채택을 촉진하고 있습니다.

부문

제품(생물학적, 합성, 생합성);최종 용도(급성기, 만성기);최종사용자(병원, 창상 치료 센터, 기타 최종사용자)

조사 대상 기업의 예(주목 33사)

  • Amarantus Bioscience Holdings, Inc.
  • BSN medical
  • ConvaTec Group PLC
  • Integra LifeSciences Corporation
  • Kerecis
  • LifeNet Health
  • Mallinckrodt
  • Medline Industries, Inc.
  • MiMedx
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Regenicin
  • Smith & Nephew
  • Tissue Regenix

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSA 24.11.27

Global Tissue Engineered Skin Substitutes Market to Reach US$5.4 Billion by 2030

The global market for Tissue Engineered Skin Substitutes estimated at US$3.1 Billion in the year 2023, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2023-2030. Biological Substitutes, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Synthetic Substitutes segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$853.0 Million While China is Forecast to Grow at 7.6% CAGR

The Tissue Engineered Skin Substitutes market in the U.S. is estimated at US$853.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$822.5 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.6% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Tissue Engineered Skin Substitutes Market - Key Trends and Drivers Summarized

How Are Tissue Engineered Skin Substitutes Revolutionizing Wound Care?

Tissue engineered skin substitutes are advanced biomaterials designed to replace damaged or lost skin tissues in patients suffering from severe burns, chronic wounds, and other skin injuries. These substitutes are developed using biocompatible scaffolds, cells, and growth factors to mimic the structure and function of natural skin, promoting faster healing and reducing scarring. Available as allogeneic, autologous, and xenogeneic grafts, tissue engineered skin substitutes provide vital solutions in reconstructive surgery, dermatology, and wound management. As healthcare systems emphasize better patient outcomes and faster recovery, tissue engineered skin substitutes have gained traction as effective alternatives to traditional skin grafts.

What Are the Key Segments in the Tissue Engineered Skin Substitutes Market?

Major product types include acellular, cellular, and composite substitutes. Acellular substitutes, made primarily from collagen or other biomaterials, hold a significant share due to their wide use in burn treatments and chronic wound management. Cellular substitutes, which contain living cells, are gaining popularity for their ability to integrate with the patient’s skin and enhance healing. Applications of tissue engineered skin substitutes cover burn management, diabetic ulcers, pressure ulcers, and reconstructive surgeries, with burn management representing the largest segment due to the critical need for rapid skin regeneration in severe cases. End-users of tissue engineered skin substitutes include hospitals, wound care centers, and specialty clinics. Hospitals lead the market, utilizing these substitutes for burn treatments, reconstructive surgeries, and chronic wound management, where rapid healing and reduced hospitalization are critical. Wound care centers use skin substitutes for treating diabetic ulcers, pressure sores, and other non-healing wounds, improving patient recovery and reducing the risk of infection. Additionally, specialty clinics employ these substitutes in cosmetic and reconstructive surgeries, ensuring better aesthetic outcomes and faster recovery times.

How Are Tissue Engineered Skin Substitutes Applied in Healthcare?

In hospitals, tissue engineered skin substitutes are used to treat severe burns, deep wounds, and post-surgical recovery, promoting faster healing and minimizing scar formation. In wound care centers, these substitutes play a critical role in managing chronic wounds like diabetic ulcers and pressure sores, where they help regenerate skin tissues and prevent infections. In reconstructive and cosmetic surgeries, skin substitutes provide aesthetic restoration and improved skin function, particularly in cases of trauma, congenital defects, and post-cancer surgeries. The use of advanced biomaterials in these substitutes also reduces the need for donor skin grafts, minimizing complications and recovery times.

What Factors Are Driving the Growth in the Tissue Engineered Skin Substitutes Market?

The growth in the Tissue Engineered Skin Substitutes market is driven by several factors, including rising incidence of burns and chronic wounds, advancements in tissue engineering, and increasing demand for better wound care solutions. Innovations like bioengineered scaffolds, growth factor-infused substitutes, and improved integration with natural tissues have expanded their applications across healthcare. The focus on improving patient outcomes, reducing recovery times, and minimizing hospital stays has further fueled demand, as tissue engineered skin substitutes offer critical benefits in wound management. Additionally, growing healthcare spending, rising awareness of advanced wound care treatments, and increased investment in regenerative medicine have contributed to market growth, encouraging the adoption of tissue engineered skin substitutes in diverse medical settings.

SCOPE OF STUDY:

The report analyzes the Tissue Engineered Skin Substitutes market in terms of US$ Thousand by the following Application; End-Use; Product, and Geographic Regions/Countries:

Segments:

Product (Biological, Synthetic, Biosynthetic); Application (Acute, Chronic); End-Use (Hospitals, Wound Care Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

  • Amarantus Bioscience Holdings, Inc.
  • BSN medical
  • ConvaTec Group PLC
  • Integra LifeSciences Corporation
  • Kerecis
  • LifeNet Health
  • Mallinckrodt
  • Medline Industries, Inc.
  • MiMedx
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Regenicin
  • Smith & Nephew
  • Tissue Regenix

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Tissue Engineered Skin Substitutes - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Use in Burn Treatment and Wound Care Spurs Market Demand
    • Advancements in Bio-Engineered Skin Solutions Drive Market Growth
    • Increasing Adoption in Diabetic Foot Ulcer Management Expands Addressable Market
    • Rising Focus on Chronic Wound Care Strengthens Business Case
    • Focus on Reducing Surgical Recovery Time Enhances Demand
    • Increasing Use of Collagen-Based and Synthetic Skin Substitutes Expands Market Opportunities
    • Advancements in 3D Bioprinting Technologies Propel Tissue Engineering Solutions
    • Growing Emphasis on Minimally Invasive Procedures Drives Adoption
    • Rising Use of Skin Substitutes in Reconstructive Surgeries Sustains Market Growth
    • Focus on Cosmetic and Aesthetic Applications Expands Market Scope
    • Increasing Focus on Developing Off-the-Shelf Skin Substitutes Generates Opportunities
    • Growing Use in Pediatric Wound Care Propels Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tissue Engineered Skin Substitutes Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Biological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Biological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biosynthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Biosynthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Acute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Acute by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Chronic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Wound Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Wound Care Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: China 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: China 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: France 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: France 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제